Publications by authors named "P Reimann"
Article Synopsis
- Older adults still face high risks of severe outcomes from COVID-19, even with the milder Omicron variant, due to weakened immune responses and insufficient data on antibody efficacy.
- A study involving 785 older patients found that those with low antibody levels (< 1,200 BAU/mL) had significantly higher mortality and critical care needs compared to those with higher levels.
- The findings suggest that monitoring antibody levels might be more effective than relying solely on vaccination status to protect older adults from severe COVID-19 outcomes.
Article Synopsis
- This study evaluates the use of durvalumab combined with platinum and gemcitabine for treating biliary tract cancers, aiming to validate previous trial results in a real-world setting and investigate how molecular profiles may affect patient outcomes.* -
- The analysis involved 102 patients from multiple cancer centers, revealing a 71.57% disease control rate and a median overall survival of 13.61 months, with younger patients showing better outcomes.* -
- Findings indicate that while no specific molecular profiles predicted better responses to durvalumab, patients receiving tailored second-line therapy showed a potential survival advantage, highlighting the need for further research in this area.*
Objectives: Despite the currently prevailing, milder Omicron variant, coronary artery disease (CAD) patients constitute a major risk group in COVID-19, exhibiting 2.6 times the mortality risk of non-CAD patients and representing over 22% of non-survivors. No data are currently available on the efficacy of antibody levels in CAD patients, nor on the relevance of vaccination status versus antibody levels for predicting severe courses and COVID-19 mortality.
View Article and Find Full Text PDFBackground: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading toradiation therapy or surgery to the bone, spinal cord compression, or hypercalcemia. The absolute value of BTA treatment in the era of immunotherapy (IO) is unknown.
Methods: Patients with bone metastases treated with immunotherapy within the Alpine Tumor Immunology Registry were compared based on whether they received an additional BTA such as denosumab or zoledronic acid.
Article Synopsis
- A retrospective study was conducted on 319 adults with early-stage non-small cell lung cancer (NSCLC) in Austria from January 2018 to December 2021, focusing on their profiles and initial treatment options.
- Key findings showed that biomarkers like PD-L1, KRAS, and EGFR were tested, with varying treatment paths for patients in different stages (StI: 82% underwent surgery, StII: 85%, StIII: 36%).
- The study highlighted that treatments were generally in line with existing guidelines, occurring before the introduction of immune checkpoint inhibitors and targeted therapies in earlier treatment stages.